| Name | Title | Contact Details |
|---|
Chromagraphics is a Santa Rosa, CA-based company in the Business Services sector.
Ramsey Consulting Inc is a Dayton, OH-based company in the Business Services sector.
Matrox Video has paved the way for video technology and innovation for over 45 years. As a market leader in designing software and hardware solutions for the broadcast and media, live entertainment, and AV/IT markets, Matrox Video combines engineering excellence with deep industry expertise to consistently deliver unique solutions that help our customers achieve their goals. Matrox Video works with global partners and customers to develop innovative products and provide superior support that address their business challenges and help them succeed. Since 1976, we have developed the reputation of continuously meeting customers need for innovative technology at the highest standards. Today, we continue to thrive at the forefront of cutting-edge technology as we pioneer reliable, interoperable, and eco-friendly software and hardware such as encoders and decoders, IP KVM extenders, video wall controllers, broadcast developer, and infrastructure products for high-tech industries. As a video technology solutions provider in these ever-changing industries, our goal has remained the same since 1976: build exceptional products and technology that solve real-world issues and empower customers to achieve their goals.
Royal Celebrity Tours is a Redmond, WA-based company in the Business Services sector.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN